These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30562434)

  • 1. [Potassium-competitive acid blocker].
    Haruma K; Suehiro M; Kawamoto H; Manabe N
    Nihon Rinsho; 2016 Aug; 74(8):1311-1315. PubMed ID: 30562434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Iwakiri K
    J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
    Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
    Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
    Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K
    Digestion; 2018; 97(1):70-75. PubMed ID: 29393198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
    Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
    Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y
    Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.
    Umezawa M; Kawami N; Hoshino S; Hoshikawa Y; Koizumi E; Takenouchi N; Hanada Y; Kaise M; Iwakiri K
    Digestion; 2018; 97(4):309-315. PubMed ID: 29514137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis.
    Takenouchi N; Hoshino S; Hoshikawa Y; Tanabe T; Koeda M; Momma E; Ishikawa Y; Kawami N; Kaise M; Iwakiri K
    Esophagus; 2020 Jan; 17(1):87-91. PubMed ID: 31679094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
    Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
    Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.